(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)acetic acid(CAS: 652-37-9)

The compound (1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)acetic acid (CAS: 652-37-9) is subject to various regulatory guidelines including GHS classification, REACH regulations, and FDA/EPA requirements. GHS classifies the compound as a carcinogen, and REACH regulations require documentation on its properties and potential risks. FDA and EPA may have specific labeling and handling requirements for this compound in the context of pharmaceutical and environmental safety.

Alternatives to (1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)acetic acid (CAS: 652-37-9) in synthesis include other purine derivatives and their analogs such as 6-mercaptopurine, thioguanine, and 6-thioguanosine. Common alternative reagents may also include nucleoside precursors and other organic compounds that can serve similar functional roles in medicinal and chemical syntheses.

Market trends for (1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)acetic acid (CAS: 652-37-9) indicate growing interest in its potential applications in pharmaceuticals and research, particularly in cancer treatment and nucleoside chemistry. Research trends focus on developing new derivatives and exploring its mechanisms of action. Market demand is expected to increase due to its potential in targeted therapies and drug development.

Waste containing (1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)acetic acid (CAS: 652-37-9) should be collected in appropriate containers and stored away from ignition sources. Handling and disposal should comply with local and national regulations, including GHS guidelines and REACH regulations. Incineration of waste may be necessary, following proper environmental protection precautions. Professional waste disposal services are recommended to ensure compliance and safety.